Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming
More events are coming soon.
Prior

February 14, 2019 8:00 AM EST
Q4 2018 Incyte Corporation Earnings Conference Call

January 07, 2019 2:00 PM PST
J. P. Morgan 37th Annual Healthcare Conference Q/A Session

January 07, 2019 1:30 PM PST
J. P. Morgan 37th Annual Healthcare Conference Presentation

SEC Filings

Filing date Description Filing Group View

A statement of beneficial ownership of common stock by certain persons

3,4,5

An amendment to the SC 13G filing

3,4,5

An amendment to the SC 13G filing

3,4,5

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536